What are the assumed reimbursement rates and payer acceptance timelines for these products?

The article you provided focuses exclusively on Tevogen Bio’s revenue outlook for its oncology pipeline and does not disclose any specifics about reimbursement rates or the expected timelines for payer acceptance of the upcoming T‑cell therapies. Consequently, there are no publicly disclosed assumptions on what price‑or‑coverage levels insurers might grant, nor any guidance on when payers are expected to adopt or reimburse the products after launch.

Without explicit reimbursement or payer‑adoption data, any valuation model must treat these inputs as “unknowns” and rely on broader market comparables (e.g., pricing and payer uptake trends for similar off‑the‑shelf T‑cell products). Traders should therefore monitor forthcoming SEC filings, investor presentations, or payer‑policy press releases from Tevogen for concrete figures before factoring payer‑reimbursement risk into the price target. In the interim, focus on the company’s projected $1 billion launch‑year revenue and the $10‑$14 billion five‑year range as the primary drivers of near‑term valuation, while treating reimbursement assumptions as a high‑uncertainty, “scenario‑dependent” variable.